Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 23:12:989080.
doi: 10.3389/fonc.2022.989080. eCollection 2022.

Synergy of Losartan and chemotherapy for patients with cholangiocarcinoma: A propensity score-matched analysis

Qing Li  1 , Zhenyu Chang  2   3 , Tianyi Wang  4 , Bing Liu  5 , Ximin Wang  4 , Xin-Yu Ge  4 , Tao Yang  4 , Qu Liu  2   3 , Wei Wang  4
Affiliations

Synergy of Losartan and chemotherapy for patients with cholangiocarcinoma: A propensity score-matched analysis

Qing Li et al. Front Oncol. .

Abstract

Background: Cholangiocarcinoma (CCA) is a malignant tumor originating from bile duct epithelial cells that no obvious clinical symptoms and specific clinical manifestations are shown in the early stage of CCA.

Methods: Propensity score matching (PSM) is a quasi-experimental method in which this study used. Patients were enrolled from Department of General surgery, First Affiliated Hospital of Jinzhou Medical University from March 1, 2010, to December 30, 2019. Totally 170 patients with CCA were enrolled in this study.

Results: We performed a 1:2 PSM study and found that patients with losartan group showed both comparable median OS (overall survival) and TTR (time to recurrence) to those in the patients without losartan group before PSM. However, after matching, patients with losartan group showed favorable median OS and TTR than those in the patients without losartan group. Then we performed Cox proportional hazards models and found that patients with losartan was an independent factor after multivariable analysis for patients with CCA. Furtherly, we sequenced serial cfDNA were performed in 10 patients with losartan and 9 patients without losartan who received adjuvant chemotherapy after tumor resection. These results showed that the treatment of losartan was related with tumor microenvironment and could be potentially useful to combine the immunotherapy for patients with CCA.

Conclusion: In conclusion, this study demonstrated that the treatment of losartan could increase the efficacy of adjuvant chemotherapy and identified as an independent survival predictor for patients with CCA. Moreover, losartan could be potentially useful to combine the immunotherapy for patients with CCA.

Keywords: Cholangio carcinoma; PSM; chemotherapy; losartan; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Survival Analysis of Patients with different treatments. (A, B): the OS and TTR for patients with or without losartan before PSM; (C, D): the OS and TTR for patients with or without losartan after PSM.
Figure 2
Figure 2
Sequenced serial cfDNA were performed in 10 patients with losartan and 9 patients without losartan who received adjuvant chemotherapy after tumor resection. (A) The changing of CfDNA in patients received losartan; (B) The changing of CfDNA in patients without losartan.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Cillo U, Fondevila C, Donadon M, Gringeri E, Mocchegiani F, Schlitt HJ, et al. . Surgery for cholangiocarcinoma. Liver Int (2019) 39 Suppl 1(Suppl Suppl 1):143–55. doi: 10.1111/liv.14089 - DOI - PMC - PubMed
    1. El-Diwany R, Pawlik TM, Ejaz A. Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am (2019) 28(4):587–99. doi: 10.1016/j.soc.2019.06.002 - DOI - PubMed
    1. Anderson C, Kim R. Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions. Cancer Treat Rev (2009) 35(4):322–7. doi: 10.1016/j.ctrv.2008.11.009 - DOI - PubMed
    1. Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, et al. . SWOG S0809: A phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol (2015) 33(24):2617–22. doi: 10.1200/jco.2014.60.2219 - DOI - PMC - PubMed
    1. Howell M, Valle JW. The role of adjuvant chemotherapy and radiotherapy for cholangiocarcinoma. Best Pract Res Clin Gastroenterol (2015) 29(2):333–43. doi: 10.1016/j.bpg.2015.03.001 - DOI - PubMed